Access and pricing information about GAVRETO™ (pralsetinib)

Important Safety Information | Full Prescribing Information | Visit Website

[pick list]
[Dear]
[Hello]

[pick list]
[Dr. Last Name]
[First Name]
[First Name Last Name]
,

As a quick but important reminder, Blueprint Medicines^™ is committed to providing your patients access to the GAVRETO^™ (pralsetinib) you prescribe them. The Case Managers at YourBlueprint^™, Blueprint Medicines' patient support services program, are ready to help connect eligible patients with financial assistance options depending on their insurance coverage situation. Visit our website to see our commitment in action, or call 1-888-BLUPRNT (1-888-258-7768) to speak to someone live.

[email fragments]

[Pricing Information for Colorado Prescribers]

In addition, I’m writing to give you important information about pricing for GAVRETO pursuant to Colorado law.

In accordance with Colorado law, H.B. 19-1131, the Wholesale Acquisition Cost (WAC) for a 30-day supply of the 400 mg starting dose for GAVRETO^™ (pralsetinib) is $19,243.20.

Generic versions of GAVRETO are not currently available.

WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia by the manufacturer. WAC does not represent actual transaction prices and does not include discounts, rebates, or other reductions in price.

In many cases, the price paid by patients for GAVRETO will be different from the GAVRETO’s reported WAC. How much a patient will pay will depend on the patient's insurance coverage. To determine the exact cost of a prescription, patients should contact their health insurance provider or specialty pharmacy.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

[Pricing Information for Vermont Prescribers]

In addition, I’m writing to give you important information about pricing for GAVRETO and comparable therapies pursuant to Vermont law.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved labels and indication for further information.
The prices listed below are Wholesale Acquisition Cost (WAC) as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about WAC of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
The prices listed here do not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

Marketed Products

GAVRETO 100 mg CAP 60s ea	$9,621.60
Other Products
ABIRATERONE ACETATE 250 mg TAB 120s ea	$2.49
AFINITOR 2.5 mg TAB ea	$59.40
AFINITOR DISPERZ 2 mg TBS ea	$25.28
ALECENSA 150 mg CAP 240s ea	$158.85
ALKERAN 2 mg TAB 50s ea	$135.94
ALUNBRIG 30 mg TAB 30s ea	$2.70
BALVERSA 3 mg TAB 56s ea	$626.46
BEXAROTENE 75 mg CAP 100s ea	$1.98
BICALUTAMIDE 50 mg TAB 30s ea	$5.00
BOSULIF 100 mg TAB 120s ea	$1.57
BRAFTOVI 75 mg CAP 120s ea	$6,938.00
BRUKINSA 80 mg CAP 120s ea	$21.25
CABOMETYX 20 mg TAB 30s ea	$1,518.22
CALQUENCE 100 mg CAP 60s ea	$2,435.42
CAPECITABINE 150 mg TAB 60s ea	$0.29
CAPECITABINE AVPAK 500 mg TAB 30s ea	$182.22
CAPRELSA 100 mg TAB 30s ea	$13.39
CASODEX 50 mg TAB 30s ea	$225.07
COMETRIQ 20 mg; 80 mg CAP 56s ea	$0.40
COPIKTRA 15 mg CAP 56s ea	$0.50
COTELLIC 20 mg TAB 63s ea	$102.98
CYCLOPHOSPHAMIDE 25 mg CAP 100s ea	$7.49
DAURISMO 25 mg TAB 60s ea	$241.96
DROXIA 200 mg CAP 60s ea	$0.76
EMCYT 140 mg CAP 100s ea	$16.03
ERIVEDGE 150 mg CAP 28s ea	$15.57
ERLEADA 60 mg TAB 120s ea	$5,047.18
ERLOTINIB HYDROCHLORIDE 25 mg TAB 30s ea	$84.39
EVEROLIMUS 2.5 mg TAB 28s ea	$0.24
FARYDAK 10 mg CAP 6s ea	$1,626.66
FLUTAMIDE 125 mg CAP 180s ea	$5.00
GILOTRIF 20 mg TAB 30s ea	$7.27
GLEEVEC 100 mg TAB 90s ea	$4.29
GLEOSTINE 5 mg CAP 5s ea	$193.91
HYCAMTIN 0.25 mg CAP 10s ea	$100.49
HYDREA 500 mg CAP 100s ea	$1.37
HYDROXYUREA 500 mg CAP 100s ea	$1.94
IBRANCE 75 mg CAP 21s ea	$592.83
ICLUSIG 15 mg TAB 30s ea	$4.59
IDHIFA 50 mg TAB 30s ea	$0.36
IMATINIB MESYLATE 100 mg TAB 30s ea	$140.00
IMBRUVICA 70 mg CAP 28s ea	$42.00
INLYTA 1 mg TAB 180s ea	$20.00
INREBIC 100 mg CAP 120s ea	$20.00
IRESSA 250 mg TAB 30s ea	$234.40
JAKAFI 5 mg TAB 60s ea	$96.90
KISQALI 200 mg TAB 14s ea	$4.50
KISQALI FEMARA CO-PACK 2.5 mg; 200 mg TAB 49s ea	$1.00
LENVIMA 4 mg; 10 mg CAP 10s ea	$141.03
LONSURF 6.14 mg-15 mg TAB 20s ea	$160.84
LORBRENA 100 mg TAB 30s ea	$193.91
LYNPARZA 150 mg TAB 60s ea	$2,000.00
LYSODREN 500 mg TAB 100s ea	$30.68
MATULANE 50 mg CAP 100s ea	$0.71
MAVENCLAD 10 mg TAB 4s ea	$5.42
MEKINIST 2 mg TAB 30s ea	$182.22
MEKTOVI 15 mg TAB 180s ea	$6,938.00
MELPHALAN 2 mg TAB 50s ea	$274.88
MERCAPTOPURINE 50 mg TAB 25s ea	$18.70
MERCAPTOPURINE 50 mg TAB 25s ea	$150.64
METHOTREXATE 2.5 mg TAB 36s ea	$10.00
METHOTREXATE SODIUM 2.5 mg TAB 36s ea	$0.86
NERLYNX 40 mg TAB 180s ea	$8,270.00
NEXAVAR 200 mg TAB 120s ea	$80.42
NILANDRON 150 mg TAB 30s ea	$868.53
NILUTAMIDE 150 mg TAB 30s ea	$246.50
NINLARO 4 mg CAP ea	$138.89
NUBEQA 300 mg TAB 120s ea	$1.52
ODOMZO 200 mg CAP 30s ea	$1,263.96
PIQRAY 250MG DAILY DOSE 50 mg; 200 mg TAB 28s ea	$19.50
POMALYST 1 mg CAP 21s ea	$0.52
RETEVMO 40 mg CAP 60s ea	$114.44
REVLIMID 2.5 mg CAP 28s ea	$868.53
RUBRACA 200 mg TAB 60s ea	$28.50
SIKLOS 1000 mg TAB 30s ea	$63.79
SPRYCEL 100 mg TAB 30s ea	$33.48
STIVARGA 40 mg TAB 28s ea	$214.80
SUTENT 12.5 mg CAP 28s ea	$192.47
TABRECTA 200 mg TAB 56s ea	$160.27
TAFINLAR 50 mg CAP 120s ea	$71.13
TAGRISSO 40 mg TAB 30s ea	$2,000.99
TALZENNA 0.25 mg CAP 30s ea	$170.10
TARCEVA 100 mg TAB 30s ea	$0.24
TARGRETIN 75 mg CAP 100s ea	$139.18
TASIGNA 150 mg CAP 28s ea	$131.39
TEMODAR 100 mg CAP 5s ea	$0.76
TEMOZOLOMIDE 5 mg CAP 5s ea	$1.18
TEMOZOLOMIDE AVPAK 100 mg CAP 20s ea	$221.25
TIBSOVO 250 mg TAB 60s ea	$1.77
TREXALL 7.5 mg TAB 30s ea	$11.88
TURALIO 200 mg CAP 120s ea	$408.91
TYKERB 250 mg TAB 150s ea	$5.06
VENCLEXTA 10 mg TAB 2s ea	$300.00
VENCLEXTA STARTER PACK 10 mg; 50 mg; 100 mg TAB 42s ea	$2.50
VERZENIO 50 mg TAB 14s ea	$0.34
VITRAKVI 25 mg CAP 60s ea	$5.48
VIZIMPRO 15 mg TAB 30s ea	$0.73
VOTRIENT 200 mg TAB 120s ea	$100.00
XALKORI 200 mg CAP 60s ea	$295.03
XELODA 150 mg TAB 60s ea	$1,263.96
XOSPATA 40 mg TAB 90s ea	$121.10
XPOVIO 20 mg TAB 12s ea	$182.22
YONSA 125 mg TAB 120s ea	$5.42
ZEJULA 100 mg CAP 30s ea	$26.72
ZELBORAF 240 mg TAB 112s ea	$1.38
ZOLINZA 100 mg CAP 120s ea	$125.08
ZORTRESS 0.25 mg TAB ea	$174.52
ZYDELIG 100 mg TAB 60s ea	$96.25
ZYKADIA 150 mg TAB 84s ea	$139.18
ZYTIGA 250 mg TAB 120s ea	$1.38

*Prices shown are for the lowest dosage and lowest unit price of each product. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the lowest unit price is reflected Chewable forms of the product are not included.

Source: Reprinted with permission by Pricecentric One by Eversana™, which uses Micromedex (Redbook) pricing methodology in the United States. Accessed June 12, 2020.

As always, please feel free to contact me at any time if I can be of further assistance.

Sincerely,

[Rep photo]

[Rep name]
[Rep title]

GAVRETO™ (pralsetinib) is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Pneumonitis occurred in 10% of patients who received GAVRETO, including 2.7% with Grade 3/4, and 0.5% with fatal reactions. Monitor for pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD.

Hypertension occurred in 29% of patients, including Grade 3 hypertension in 14% of patients. Overall, 7% had their dose interrupted and 3.2% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue GAVRETO based on the severity.

Hepatotoxicity: Serious hepatic adverse reactions occurred in 2.1% of patients treated with GAVRETO. Increased AST occurred in 69% of patients, including Grade 3/4 in 5.4% and increased ALT occurred in 46% of patients, including Grade 3/4 in 6%. The median time to first onset for increased AST was 15 days (range: 5 days to 1.5 years) and increased ALT was 22 days (range: 7 days to 1.7 years). Monitor AST and ALT prior to initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on severity.

Grade ≥ 3 hemorrhagic events occurred in 2.5% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event. Permanently discontinue GAVRETO in patients with severe or life-threatening hemorrhage.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, GAVRETO has the potential to adversely affect wound healing. Withhold GAVRETO for at least 5 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution of wound healing complications has not been established.

Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the final dose. Advise women not to breastfeed during treatment with GAVRETO and for 1 week after the final dose.

Common adverse reactions (≥25%) were fatigue, constipation, musculoskeletal pain, and hypertension. Common Grade 3-4 laboratory abnormalities (≥2%) were decreased lymphocytes, decreased neutrophils, decreased phosphate, decreased hemoglobin, decreased sodium, decreased calcium (corrected) and increased alanine aminotransferase (ALT).

Avoid coadministration with strong CYP3A inhibitors. Avoid coadministration of GAVRETO with combined P-gp and strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the GAVRETO dose. Avoid coadministration of GAVRETO with strong CYP3A inducers. If coadministration cannot be avoided, increase the GAVRETO dose.

Please click here to see the full Prescribing Information for GAVRETO.

This e-mail is intended for U.S. healthcare professionals only.

GAVRETO, Blueprint Medicines, YourBlueprint and associated logos are
trademarks of Blueprint Medicines Corporation.

Blueprint Medicines Corporation
45 Sidney Street, Cambridge, MA 02139

09/2020 USBP-PRP-20.062.1